Every Form 4 that Repligen (RGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGEN filings page.
REPLIGEN CORP (RGEN) reported insider equity activity by Chief Accounting Officer Violetta Hughes. On March 5, 2026, she received a grant of 2,466 restricted stock units, each representing a contingent right to one share of common stock that vests in equal annual installments over four years. On September 1, 2026, 277 shares of common stock were withheld by Repligen to satisfy tax withholding obligations arising from the release of restricted stock units, at a reference value of $170.02 per share.
REPLIGEN CORP (RGEN) reported Form 4 activity by Chief Executive Officer Olivier Loeillot involving an option exercise and share sale. On August 20, 2026, he exercised a stock option to acquire 5,426 shares of common stock at an exercise price of $141.79 per share, and on the same date sold 5,426 shares of common stock at $180.00 per share. The option exercise reduced the reported option position by 5,426 shares, leaving 10,852 stock options outstanding after the transaction at the same exercise price and with an expiration date of September 3, 2034. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025, and that an additional 5,426 shares will vest on each of September 3, 2026 and September 3, 2027.
Repligen Corp Chief Financial Officer Jason K. Garland reported selling 530 shares of Common Stock on July 16, 2026 at $150.0000 per share, in a transaction described as a sale in an open market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on December 8, 2025, and he now directly holds 18,829 shares.
REPLIGEN CORP CFO Jason K. Garland sold a small block of company stock in a pre-planned transaction. On the reported date, he completed an open-market sale of 733 shares of common stock at a price of $145 per share. After this sale, he directly owns 19,359 shares of Repligen common stock. The filing notes that the sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating the transaction was pre-scheduled rather than timed discretionarily.
Repligen Corporation director Martin D. Madaus reported equity awards, not open-market trades. He received 995 restricted stock units, each representing one share of common stock. These units vest on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and settlement has been deferred until after his board service ends.
He was also granted stock options on 2,239 shares at an exercise price of $103.38 per share, vesting on the same schedule and expiring on May 14, 2036. Following these awards, he directly holds 6,581 common shares and indirectly holds additional shares through a spouse trust with 11 shares and a 2011 revocable trust with 1,800 shares.
Repligen Corporation director Konstantin Konstantinov received new equity awards consisting of restricted stock units and stock options. He was granted 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 3,889 shares after the award.
He was also granted stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, with the options expiring on May 14, 2036. Both the restricted stock units and the option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of shareholders.
Repligen Corp director Rohin Mhatre reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 5,014 shares after the grant.
He was also granted stock options for 2,239 shares of common stock at an exercise price of $103.38 per share. These options are exercisable starting on May 14, 2027 and expire on May 14, 2036. The restricted stock units and options each vest in full on the earlier of May 14, 2027 or the date of the next annual meeting of shareholders, which has not yet been determined.
Repligen Corporation director Carrie Eglinton Manner reported compensation-related equity awards, not open-market trades. She was granted 995 restricted stock units, each representing a contingent right to receive one share of Repligen common stock. She also received stock options for 2,239 shares at an exercise price of $103.38 per share.
The restricted stock units and the stock option award each vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders. Following these grants, she holds 5,461 shares of common stock directly and 2,239 stock options.
Repligen Corp director Margaret Pax reported equity awards consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one future share of common stock, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the award vesting on the same schedule. Following the grant, she directly holds 3,011 shares of common stock.
Repligen Corp director Karen A. Dawes received equity compensation consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one share of common stock, which vest on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036. Following these awards, she directly holds 92,816 common shares. These are compensation grants, not open‑market purchases or sales.
REPLIGEN CORP director Glenn P. Muir reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of common stock, which vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting.
Muir also received stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the same vesting schedule. Following these awards, he holds 40,051 shares of common stock directly and 2,239 stock options. The RSUs will be settled in shares after his service as a director ends, in line with his deferral election.
Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants. He was awarded 995 restricted stock units, each representing one share of Common Stock, and 2,239 stock options with an exercise price of $103.38 per share.
The RSUs and option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting. Barthelemy has elected to defer settlement of the RSUs under Repligen’s Deferred Compensation Plan for Non-Employee Directors, with shares to be delivered after his service as a director ends. Following these grants, he directly holds 5,436 shares of Common Stock and 2,239 options.
REPLIGEN CORP director Glenn P. Muir exercised stock options to acquire 2,434 shares of Common Stock. The options were exercised at $38.76 per share on May 7, 2026, and were fully vested and exercisable. Following the transaction, Muir directly holds 39,056 Common Stock shares. A corresponding derivative entry shows 2,434 Stock Option (Right to Buy) units exercised with an exercise price of $38.76 and an expiration date of May 18, 2027. No share sales or tax-withholding dispositions are reported in this Form 4.
Repligen Corp chief product officer Brian Robb had 334 common shares withheld on the release of restricted stock units, at a value of $126.43 per share. These shares were retained by the company to cover his tax obligations, not sold on the open market, leaving him with 7,985 shares held directly.
Repligen Corp Chief Executive Officer Olivier Loeillot sold 3,832 shares of common stock in an open-market transaction at $140 per share.
The sale was executed pursuant to a Rule 10b5-1 trading plan, and he continues to hold 54,246 shares of Repligen common stock directly after the transaction.
Repligen Corporation Senior VP of R&D Ralf Kuriyel received new equity awards in the form of stock options and restricted stock units. He was granted 5,669 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring on March 5, 2036. One third of these options will vest and become exercisable on each of March 5, 2027, March 5, 2028, and March 5, 2029. He also received 5,284 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date. After the restricted stock unit grant, his direct Common Stock holdings increased to 20,062 shares.
Repligen Corporation Chief Executive Officer Olivier Loeillot received new equity awards that increase his direct ownership stake. He was granted 25,890 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring in 2036, vesting in three equal annual installments on March 5, 2027, 2028 and 2029. He also received 24,134 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years beginning on the first anniversary of the grant date. Following these awards, his direct Common Stock holdings total 58,078 shares, and the restricted stock units will be settled only in shares when they vest.
Repligen Corporation’s Chief Operating Officer James Bylund received new equity awards. He was granted stock options for 8,315 shares of Common Stock at an exercise price of $141.91 per share, expiring on March 5, 2036, vesting in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also awarded 7,751 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date. Following these grants, he holds 25,423 Common Stock shares directly.
Repligen Corporation CFO Jason K. Garland reported equity compensation awards consisting of stock options and restricted stock units. He received 8,315 stock options with an exercise price of $141.91 per share, expiring on March 5, 2036, which vest in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also granted 7,751 restricted stock units, vesting in equal annual installments over three years beginning on the first anniversary of the grant date, each unit representing one share of common stock. Following the award, his direct common stock holdings total 20,092 shares.
Repligen Corp Chief Operating Officer James Bylund reported routine equity compensation activity. He acquired 125 shares of common stock at no cost upon the release of a Performance Stock Unit award tied to pre-established performance criteria, and 62 shares were withheld to cover related tax obligations. After these transactions, he directly holds 17,672 common shares.
Repligen Corp Senior VP R&D Ralf Kuriyel reported equity compensation activity involving common stock. He acquired 125 shares at no cost upon vesting of a previously granted performance stock unit award, after the company met pre-set performance goals. To cover related tax obligations, 42 shares were disposed of and withheld by the company, leaving him with 14,778 directly owned shares.
Repligen Corporation’s Chief Operating Officer James Bylund reported two share dispositions that were automatically used to cover taxes on vesting stock awards, rather than open-market sales. On February 27, 2026, 1,478 common shares at $128.73 per share were withheld, and on March 2, 2026, 2,433 shares at $124.97 per share were withheld.
These shares were retained by the company to satisfy Bylund’s tax withholding obligations triggered by the release of restricted stock units. After the March 2 withholding, Bylund directly owned 17,609 Repligen common shares.
Repligen Corp Chief Executive Officer Olivier Loeillot reported two Form 4 transactions where shares were withheld to cover taxes on restricted stock units. On February 27, 2026, 344 shares of common stock were disposed of at $128.73 per share, leaving 35,554 shares directly owned. On March 2, 2026, 1,610 shares were disposed of at $124.97 per share, leaving 33,944 shares directly owned. These are tax-withholding dispositions, not open-market sales.
REPLIGEN CORP director Anthony Hunt reported a tax-related share disposition. On the release of restricted stock units, 9,897 shares of common stock were withheld by the company to cover his tax withholding obligations at a reference price of $124.97 per share. After this non‑open‑market transaction, he directly owned 89,062 shares.
Repligen Corporation’s CFO Jason K. Garland reported routine tax-related share withholdings. On March 2, 2026, the company withheld 715 shares of common stock at $124.97 per share, and on February 27, 2026, it withheld 327 shares at $128.73 per share to satisfy tax obligations triggered by restricted stock unit releases. These dispositions were for tax withholding rather than open-market sales.
Repligen Corp senior vice president of R&D Ralf Kuriyel reported two tax-related share dispositions. On February 27, 2026, the company withheld 444 shares of common stock at $128.73 to cover tax obligations from restricted stock units vesting.
On March 2, 2026, the company similarly withheld 923 shares at $124.97. After the later transaction, Kuriyel directly owned 14,695 common shares. These were tax-withholding events rather than open-market sales.
Repligen Corp chief product officer Brian Robb reported a small share disposition tied to taxes rather than an open-market trade. On the reported date, 221 shares of common stock were withheld by the company at $124.97 per share to cover tax obligations arising from the release of restricted stock units. After this tax-withholding transaction, Robb’s directly held common stock balance was 8,319 shares.
Repligen Corporation reported new equity awards to its Chief Product Officer, Douglass Brian Robb. On 12/31/2025, he received 2,288 restricted stock units, each representing one share of Repligen common stock. These restricted stock units vest in substantially equal annual installments over three years, beginning on the first anniversary of the grant date, and are settled only in shares of common stock.
On the same date, he was also granted a stock option for 2,143 shares of common stock at an exercise price of $163.86 per share, expiring on 12/31/2035. Following the restricted stock award, he directly beneficially owned 8,540 shares of common stock, and 2,143 stock options were beneficially owned directly after the option grant.
A director of Repligen Corp (RGEN) reported a small open-market sale of company stock. On 12/17/2025, the director sold 275 shares of Repligen common stock at a price of $161 per share, as shown in Table I of the filing. After this transaction, the director continued to beneficially own 91,821 shares of Repligen common stock, held as a direct ownership position. The report was filed as a Form 4 for one reporting person, indicating routine insider transaction disclosure.
Repligen Corporation reported that one of its directors exercised a stock option for common shares. On 12/16/2025, the director acquired 3,366 shares of common stock through an option exercise at a price of $26.12 per share, increasing the director’s direct beneficial ownership to 36,622 common shares after the transaction. The related stock option, which is fully vested and exercisable, covers 3,366 shares of common stock and carries an exercise price of $26.12 with an expiration date of May 11, 2026.
A director of Repligen Corporation reported an insider transfer of 2,000 shares of Repligen common stock on 12/04/2025. After this transaction, the reporting person beneficially owns 98,959 shares of common stock in direct form. The filing describes the move as a transfer of shares in which the reporting person is a joint tenant with right of survivorship, indicating a change in how the shares are held rather than a typical market sale.
Repligen Corporation (RGEN) reported an insider stock sale by its Chief Executive Officer, who is also a director. On 11/25/2025, the executive sold 7,041 shares of common stock at a price of $170 per share, as shown in a Form 4 filing. After this transaction, the executive directly held 35,898 shares of Repligen common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a set schedule.
Repligen Corporation's Chief Operating Officer reported a stock sale in a Form 4. On 11/18/2025, the officer sold 2,191 shares of Repligen common stock in an open market transaction coded "S" (sale). The weighted average sale price was $151.21 per share, with individual trades executed between $151.21 and $151.62.
After this transaction, the officer directly beneficially owns 21,520 shares of Repligen common stock. The filing notes that detailed trade breakdowns by price within the range are available upon request from the company, its security holders, or the SEC staff.
Repligen Corporation director reported several transactions in company stock. On 11/13/2025, the director sold multiple blocks of common stock in open-market transactions at weighted average prices ranging from $151.01 to $157.11, each sale covering different share amounts. After these sales, the director beneficially owned 80,743 shares of Repligen common stock in direct form. The director also exercised a stock option for 2,952 shares at an exercise price of $33.87, which increased directly held shares while reducing the option position.
Repligen (RGEN) reported an insider transaction by a director on 11/12/2025. The director exercised 25,000 stock options at $33.87 and, on the same day, sold 25,000 common shares in multiple trades under a Rule 10b5-1 plan adopted on December 9, 2024. Sale prices were reported as weighted averages ranging from $154.92 to $158.51.
Following these transactions, the director directly owned 100,743 shares. The option reported expires on 03/01/2028, with 157,344 derivative securities beneficially owned after the transactions, and remaining tranches vesting 28,777 on 03/01/2026 and 28,778 on 03/01/2027.
Repligen Corporation reporting person Olivier Loeillot, who is listed as both a Director and the Chief Executive Officer, recorded a sale of common stock on 10/02/2025. The filing shows 1,248 shares were disposed of at a price of $145.23 per share, with 42,939 shares remaining beneficially owned after the transaction. The reported sale represents shares withheld by the issuer to satisfy tax withholding obligations arising from the release of restricted stock units, not an open-market purchase or voluntary sale. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.
Repligen Corp (RGEN) Chief Financial Officer Jason K. Garland reported a non-derivative disposition on 09/25/2025 involving 412 shares of Common Stock sold at a price of $121.68 per share. The filing shows 13,383 shares remained beneficially owned by the reporting person after the transaction. The form identifies the transaction as related to tax withholding: the 412 shares were withheld by the issuer to satisfy the reporting person's tax withholding obligations upon the release of restricted stock units.